These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 23713998)

  • 1. What can be done to improve confidence and trust in the safety of the system for pharmaceutical products?
    Edwards BD; Whalen MD; Powell SM
    Curr Drug Saf; 2013 Feb; 8(1):1-3. PubMed ID: 23713998
    [No Abstract]   [Full Text] [Related]  

  • 2. Shared REMS programs expanded in 2012.
    Traynor K
    Am J Health Syst Pharm; 2013 Feb; 70(4):298, 303. PubMed ID: 23370134
    [No Abstract]   [Full Text] [Related]  

  • 3. Where are risk evaluation and mitigation strategies headed?
    Johnson PE
    Am J Health Syst Pharm; 2010 Sep; 67(18):1511. PubMed ID: 20811027
    [No Abstract]   [Full Text] [Related]  

  • 4. Issues related to risk evaluation and mitigation strategies in health-system pharmacy.
    Coffey J
    Am J Health Syst Pharm; 2010 Sep; 67(18):1512. PubMed ID: 20811028
    [No Abstract]   [Full Text] [Related]  

  • 5. Defining the pharmaceutical system to support proactive drug safety.
    Lewis VR; Hernandez A; Meadors M
    Curr Drug Saf; 2013 Feb; 8(1):25-39. PubMed ID: 23656445
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk evaluation and mitigation strategies: challenges and opportunities for health-system pharmacists.
    Stubbings J; Joshi RA; Hoffman JM
    Am J Health Syst Pharm; 2010 Sep; 67(18):1547-54. PubMed ID: 20811034
    [No Abstract]   [Full Text] [Related]  

  • 7. Using technology to enhance measurement of drug-use safety.
    Schneider PJ
    Am J Health Syst Pharm; 2002 Dec; 59(23):2330-2. PubMed ID: 12489374
    [No Abstract]   [Full Text] [Related]  

  • 8. How the FDA handles GI drug safety.
    Lewis JH
    Am J Gastroenterol; 2012 Aug; 107(8):1264; author reply 1264-5. PubMed ID: 22859005
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA moves closer to new requirements for NTI drugs.
    Traynor K
    Am J Health Syst Pharm; 2011 Sep; 68(17):1568-9, 1570. PubMed ID: 21856797
    [No Abstract]   [Full Text] [Related]  

  • 10. Present attitudes of governmental drug regulatory agencies.
    Noel PR
    Int J Clin Pharmacol; 1973 Apr; 7(2):168-77. PubMed ID: 4731283
    [No Abstract]   [Full Text] [Related]  

  • 11. The drug regulatory system of the United States Food and Drug Administration: a defense of current requirements for safety and efficacy.
    Simmons HE
    Int J Health Serv; 1974; 4(1):95-107. PubMed ID: 4829901
    [No Abstract]   [Full Text] [Related]  

  • 12. Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
    Croft DE; Wykoff CC; Michels S; Chakravarthy U; Cruess AF
    Am J Ophthalmol; 2016 Sep; 169():xiv-xvi. PubMed ID: 27485923
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk Management for Materials and Components Used in Orally Inhaled and Nasal Drug Products.
    Stults CL; Reckzuegel G; Bailey A; Petersen J; Dick L; Feinberg T; Feilden A; Miller S; Connors J; Nagao LM
    Pharm Res; 2016 Jan; 33(1):1-17. PubMed ID: 26334501
    [No Abstract]   [Full Text] [Related]  

  • 14. A perspective on US drug reimportation.
    Choudhry NK; Detsky AS
    JAMA; 2005 Jan; 293(3):358-62. PubMed ID: 15657329
    [No Abstract]   [Full Text] [Related]  

  • 15. The Food and Drug Administration risk evaluation and mitigation strategy.
    Craig DS
    J Pain Palliat Care Pharmacother; 2010 Jun; 24(2):145-8. PubMed ID: 20504137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On how to improve drug use to minimise risks to patients.
    Woodward S
    Nurs Times; 2009 Sep 8-14; 105(35):33. PubMed ID: 19791677
    [No Abstract]   [Full Text] [Related]  

  • 17. Counterfeit drugs pose growing health threat.
    Traynor K
    Am J Health Syst Pharm; 2010 Nov; 67(22):1896, 1898. PubMed ID: 21048204
    [No Abstract]   [Full Text] [Related]  

  • 18. [Risk management--adverse effects of pharmaceutical products. Interpretation of the drug package inserts].
    Mochizuki M
    Nihon Jibiinkoka Gakkai Kaiho; 2005 Aug; 108(8):814-7. PubMed ID: 16267911
    [No Abstract]   [Full Text] [Related]  

  • 19. Communication of medical product risk: how effective is effective enough?
    Goldman SA
    Drug Saf; 2004; 27(8):519-34. PubMed ID: 15154825
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug doses bring liability if not adequately monitored.
    Hosp Risk Manage; 1982 May; 4(5):61-2. PubMed ID: 10317338
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.